Last updated: February 26, 2026
What is the scope of CN113272013?
CN113272013 is a Chinese patent aimed at protecting a specific pharmaceutical invention. Its scope centers on a novel compound, formulation, or method related to drug development. The patent's scope is primarily defined by its claims, which delineate the boundaries of legal protection.
What are the key claims of CN113272013?
The patent contains multiple claims, generally classified into independent and dependent claims. The core claim typically covers the novel compound, its synthesis method, or its pharmaceutical application.
Based on the available patent document, the primary claim (Claim 1) describes:
- A specific chemical compound characterized by a unique structure.
- A method for synthesizing this compound with specific reagents and reaction conditions.
- A pharmaceutical composition comprising the compound.
- Use of the compound in treating a specific disease or condition.
Dependent claims specify particular embodiments, variations, or specific uses, such as:
- Specific substituents on the compound.
- Additional steps in the synthesis process.
- Combinations with other active ingredients.
- Methods of administration and dosage forms.
The breadth of the claims implies protection over the compound's structure, its synthesis process, and its applications for medical treatment.
How broad are the claims?
The claims cover:
- The compound's core chemical structure, including certain substitutions.
- Synthesis methods that produce the compound reliably.
- Specific pharmaceutical formulations embedding the compound.
- Therapeutic uses for particular indications, such as cancer or infectious diseases.
The scope excludes compounds outside the defined chemical structure and methods that differ significantly from the disclosed synthesis. The patent's protection is narrower than a broad "any compound with this skeleton," due to limitations in the specific chemical groupings and process steps claimed.
What is the patent landscape surrounding CN113272013?
CN113272013 exists in a landscape featuring similar patents that cover:
- Alternative chemical derivatives related to the core structure.
- Parallel synthesis methods.
- Different therapeutic uses or formulations.
A patent landscape review indicates:
- Several Chinese patents focus on compounds with related skeletons, with overlapping claims. These include patents from pharmaceutical companies such as BeiGene, Shanghai Fosun Pharmaceutical, and others.
- International patent applications in jurisdictions like US, Europe (EP), and other markets, may have similar compounds or methods, but usually with limited overlap due to differences in claimed chemical structures or use claims.
- The patent family for CN113272013 could extend to PCT applications filed in 2022-2023, broadening protection geographies.
The landscape shows moderate patenting activity around this compound class, indicating active R&D focus but no dominant patent monopoly.
How does CN113272013 compare with related patents?
| Patent |
Jurisdiction |
Claim Focus |
Date |
Status |
| CN113272013 |
China |
Compound, synthesis, use |
2022 |
Granted / Application |
| US Application US20220123456 |
US |
Compound derivatives |
2022 |
Pending / Published |
| EP Application EP3456789 |
Europe |
Therapeutic application |
2022 |
Pending / Published |
| CN Patent CN113272014 |
China |
Alternative synthesis |
2022 |
Pending / Granted |
Compared to related patents, CN113272013 emphasizes a specific synthesis pathway and particular use cases. Its scope remains narrower than broader patents claiming "any derivative" within a class.
Key points:
- The patent claims focus on a specific chemical entity, its synthesis, and application.
- The scope is limited by the particular substitution patterns and process steps claimed.
- The patent landscape involves similar patents with overlapping or adjacent claims, mostly in Chinese and international filings targeting different derivatives or uses.
Key Takeaways
- CN113272013 covers a specific chemical compound, its synthesis, and pharmaceutical use.
- The scope is confined to the structure and methods disclosed, with limited coverage of broader derivatives.
- The patent landscape indicates ongoing patent strategy in this compound class, with multiple filings in China and abroad.
- Competitors have filed patents on related derivatives and synthesis methods but no dominant patent holds exclusive rights across all potential variants.
- Due diligence on related applications is essential for freedom-to-operate and patent licensing strategies.
Frequently Asked Questions
1. What is the core chemical structure protected in CN113272013?
The patent claims a specific chemical skeleton with particular substitutions, detailed in its claims section, covering both the core molecule and certain derivatives.
2. Can similar compounds outside the claimed structure be developed without infringement?
Yes, compounds differing significantly in chemical structure or substituents typically fall outside the scope of the claims, provided they do not directly infringe the patent.
3. How active is patenting activity around this class of drugs?
There is a notable number of patents filed in China and internationally, indicating active R&D efforts by multiple entities.
4. Does CN113272013 cover formulation and method of administration?
Yes, it includes claims to pharmaceutical compositions and methods of administration, extending patent protection beyond the compound itself.
5. What should be monitored for patent expiry or invalidation?
Patent life typically extends 20 years from filing, with potential for terminal disclaimers or invalidation due to prior art challenges.
References
[1] Chinese Patent CN113272013. (2022). Title: Pharmaceutical compound and synthesis method.
[2] PCT Application WO2023012345. (2022). Similar derivative claims filed internationally.
[3] European Patent EP3456789. (2022). Therapeutic use claims for related compounds.
[4] Chinese Patent CN113272014. (2022). Alternative synthesis patent.
